Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

MS drug has fewer injection reactions

  • Comment
A new formulation of interferon beta-1a (Rebif) has been launched for relapsing remitting multiple sclerosis, which has a near three-fold reduction in injection-site reactions.

The new formulation is the first therapy for multiple sclerosis that is serum-free both from animal (foetal bovine serum) and human (human serum albumin) derived components in either the manufacturing process or as excipients, claims its manufacturer Merck Serono.

The new formulation was approved on August and will be phased in to replace the original formulation from this month.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.